Clinical Overview
Chlordiazepoxide is a long-acting benzodiazepine available as monotherapy (Librium) for anxiety and alcohol withdrawal, and in combination with amitriptyline (Limbitrol) for depression with anxiety. It was the first benzodiazepine developed and has a very long half-life, making it suitable for conditions requiring sustained anxiolytic effects.
Primary Clinical Applications
Chlordiazepoxide monotherapy is indicated for anxiety disorders and acute alcohol withdrawal syndrome. The combination product Limbitrol is specifically indicated for moderate to severe depression associated with moderate to severe anxiety, providing both antidepressant and anxiolytic effects.
Mechanism and Clinical Profile
Chlordiazepoxide enhances GABA activity at benzodiazepine receptors, providing anxiolytic, sedative, and anticonvulsant effects. Its very long half-life (5-30 hours) and active metabolites provide sustained therapeutic effects but increase accumulation risk, particularly in elderly patients.
Combination Benefits
The Limbitrol combination provides the antidepressant effects of amitriptyline with the anxiolytic effects of chlordiazepoxide, making it suitable for patients with mixed depression and anxiety symptoms. However, it combines the side effects and contraindications of both drug classes.
Prescribing Information
Dosing & Administration
Anxiety Disorders (Librium monotherapy) – Adults:
- Mild-moderate anxiety: 5-10 mg 3-4 times daily
- Severe anxiety: 20-25 mg 3-4 times daily
Alcohol Withdrawal (Librium):
- Initial: 50-100 mg, repeat as needed up to 300 mg daily
- Maintenance: Reduce dose gradually as symptoms subside
Depression with Anxiety (Limbitrol):
- Initial: 3-4 tablets daily in divided doses (5mg/12.5mg strength)
- Limbitrol DS: 3-4 tablets daily (10mg/25mg strength)
- Maximum: 6 tablets daily
- Elderly: Reduce dose significantly
Administration:
- Take with food to reduce GI upset
- Largest portion of daily dose may be taken at bedtime
Indications
- Chlordiazepoxide (Librium): Anxiety disorders, acute alcohol withdrawal
- Limbitrol: Moderate to severe depression with moderate to severe anxiety
Contraindications
- Hypersensitivity to benzodiazepines or tricyclics (Limbitrol)
- Acute narrow-angle glaucoma
- Severe respiratory insufficiency
- Sleep apnea syndrome
- Limbitrol additional: Recent MI, MAOI use within 14 days
Warnings & Precautions
- Boxed Warning: Risk of abuse, misuse, dependence; respiratory depression with opioids
- Limbitrol additional Boxed Warning: Increased suicidal risk in patients under 25 years
- Physical dependence: Risk increases with dose and duration
- Withdrawal syndrome: Taper gradually, may be prolonged due to long half-life
- Cognitive impairment: May affect memory and concentration
- Falls risk: Particularly in elderly due to long-acting metabolites
Drug Interactions
- Opioids: Increased risk of respiratory depression and death
- CNS depressants: Enhanced sedation and respiratory depression
- Alcohol: Dangerous potentiation of effects
- Limbitrol additional: MAOIs, anticholinergics, CYP2D6 inhibitors
Adverse Reactions
Chlordiazepoxide:
- Drowsiness, ataxia, confusion, dizziness
Limbitrol (combination effects):
- Sedation, dry mouth, constipation, blurred vision
- Orthostatic hypotension, weight gain
Serious:
- Respiratory depression, severe withdrawal syndrome
- Limbitrol: Cardiac arrhythmias, anticholinergic toxicity
Special Populations
- Elderly: Significantly increased sensitivity, start with much lower doses
- Hepatic Impairment: Use caution, may require dose reduction
- Pregnancy: Category D – avoid in pregnancy
- Very long half-life: High risk of accumulation, especially problematic in elderly
</ul
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
